uniQure N.V. (FRA:UQ1)

Market Cap	1.19B +63.9%
Revenue (ttm)	13.42M -44.9%
Net Income	-200.41M
EPS	-3.70
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	700
Average Volume	88
Open	20.05
Previous Close	19.45
Day's Range	20.05 - 20.40
52-Week Range	7.21 - 60.50
Beta	n/a
RSI	49.91
Earnings Date	Feb 27, 2026

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 209
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UQ1

Financial Performance

In 2024, uniQure's revenue was $27.12 million, an increase of 71.17% compared to the previous year's $15.84 million. Losses were -$239.56 million, -22.34% less than in 2023.

Financial numbers in USD